RecruitingNCT05745961

Quantifying 18kDa TSPO Expression in the Lung in Pulmonary Artery Hypertension (PAH)

Studying Drug- or toxin-induced pulmonary arterial hypertension

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Imperial College London
Principal Investigator
Martin Wilkins
Imperial College London
Intervention
TSPO PET scan (11C-PBR28)(radiation)
Enrollment
6 enrolled
Eligibility
25-75 years · All sexes
Timeline
20232025

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05745961 on ClinicalTrials.gov

Other trials for Drug- or toxin-induced pulmonary arterial hypertension

Additional recruiting or active studies for the same condition.

See all trials for Drug- or toxin-induced pulmonary arterial hypertension

← Back to all trials